Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Pharma Executives Need Convincing About Value-Based Contracts

Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.

Pricing Debate Pricing Strategies Policy & Regulation

Sanofi And NIH To Test 3-In-1 Antibody In HIV After Monkey Trial Success

Sanofi's focus on developing multi-specific therapies is being turned to HIV.

Clinical Trials Companies Research & Development

Provention Builds On J&J Disease Intervention Model

Founded earlier in 2017 with a plan of making quick "go/no-go" development decisions based on objective data, Provention taps into Johnson & Johnson for a pair of IBD candidates.

Deals Business Strategies Gastrointestinal
Advertisement

Report: Women Eschew Life Science Companies That Lack Female Leadership

MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.

Human Capital Leadership Business Strategies


 Recent Tweets from Scrip


Commercial Explore this Topic

Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance

Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.

StartUps and SMEs Business Strategies Immune Disorders

Zai Lab Soars On Nasdaq Debut

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Financing China StartUps and SMEs

Venter's Synthetic Genomics Sued For Gender Discrimination

Synthetic Genomics, co-founded by genomic pioneer Craig Venter, has been sued by its former intellectual property chief for gender discrimination – a claim that CEO Oliver Fetzer believes to be "without merit."

Legal Issues Human Capital

APOLLO Success Clears Alnylam For Lift-Off

Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease. 

Clinical Trials Drug Safety

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.

Biosimilars Legal Issues

Cipla Secures Ex-FDA Official As Compliance Head

Indian firms have been making extensive efforts to improve their compliance record, including getting on board top-notch global talent. Cipla, which recently appointed a new head of respiratory manufacturing, has tapped an ex-FDA investigator as its audit and compliance director.

Appointments Companies

More Is Better? UK Crowdfunding Platform Selects First Firms

Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.

Financing United Kingdom

Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016

Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.

Business Strategies Leadership

Policy & Regulation Explore this Topic

Once-Trusted Investment Advisor Burrill Faces Criminal Fraud Charges

A federal grand jury indicted Steven Burrill and an associate on charges of fraud and tax evasion regarding investment funds run by the San Francisco-based life science advisor, who settled a related SEC claim in 2016. If convicted, he could spend decades in prison and pay millions in fines.

Legal Issues Policy & Regulation Financing

Merck KGaA/Pfizer Get Europe OK For Bavencio In Rare Skin Cancer

The Merkel cell carcinoma area is very niche but getting approval means that Merck and Pfizer can now prepare to compete with the likes of Opdivo and Keytruda in the European PD-1/PD-L1 space.

Approvals ImmunoOncology

Venter's Synthetic Genomics Sued For Gender Discrimination

Synthetic Genomics, co-founded by genomic pioneer Craig Venter, has been sued by its former intellectual property chief for gender discrimination – a claim that CEO Oliver Fetzer believes to be "without merit."

Legal Issues Human Capital

EU Moves To RATIFY Novartis' Rydapt for AML

Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots its commercial launch in Europe.

Cancer Approvals

Research & Development Explore this Topic

Tyme Ticks On With Mid-Stage Development Of A Broad Cancer Therapy

The small biotech presented positive interim data from a Phase II trial testing its lead candidate SM-88 in prostate cancer at ESMO and is gearing up to initiate a trial in pancreatice cancer.

Cancer Companies Business Strategies

APOLLO Success Clears Alnylam For Lift-Off

Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease. 

Clinical Trials Drug Safety

Expanded IMPACT For GSK Respiratory Business From New Trelegy Data

Headline data from GlaxoSmithKline's IMPACT study comparing its new triple therapy Trelegy Ellipta with the company's dual therapies Breo/Relvar Ellipta and Anoro Ellipta support the product's ability to reduce exacerbations in more severe COPD. However, the benefit of IMPACT in expanding GSK's respiratory sales may be limited given pricing pressures and the make-up of GSK's current portfolio.

Clinical Trials Respiratory

Sanofi Ready To Pull The Plug On Regeneron 'Life Support'

Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.

Deals Research & Development
UsernamePublicRestriction

Register

Advertisement